Search
Successful Launch of Phase I Clinical Trial for AlphaNano's Herpes Zoster mRNA Vaccine
2025-08-23 /
Read about 0 minute
Author：小编
AlphaNano Biotechnology Co., Ltd. has successfully initiated the Phase I clinical trial for its independently developed herpes zoster mRNA vaccine, marking a milestone in its preventive vaccine research and development pipeline. Leveraging three core technologies—the "SMART Delivery Platform, Immune Regulation Platform, and AI-based mRNA Sequence Design Platform"—AlphaNano has achieved coordinated innovation across multiple disease treatment pipelines. This progress underscores the company's deep accumulation and groundbreaking advancements in the realm of mRNA technology.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
